<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904692</url>
  </required_header>
  <id_info>
    <org_study_id>BC-07492</org_study_id>
    <nct_id>NCT04904692</nct_id>
  </id_info>
  <brief_title>Virological and Immunological Monitoring in Patients (Suspected of/Confirmed With) COVID-19</brief_title>
  <acronym>Co-Vim</acronym>
  <official_title>Virological and Immunological Monitoring in Patients (Suspected of/Confirmed With) COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fund for Scientific Research, Flanders, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chan Zuckerberg Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flanders Institute for Biotechnology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, observational multicentric study. The study population entails&#xD;
      adult patients hospitalized with a high clinical suspicion of COVID-19 and consists of two&#xD;
      study arms (SARS-CoV2- vs. SARS-CoV2+).This combined fundamental research project has a dual&#xD;
      goal: on the one hand assessing immunological predisposing factors for severe infection and&#xD;
      investigating the immunological impact of SARS-CoV2 infection, on the other hand studying&#xD;
      viral characteristics. Furthermore, a substudy will examine the pharmacokinetics and&#xD;
      pharmacodynamics of hydroxychloroquine in patients receiving this antiviral treatment (REVIVE&#xD;
      susbstudy). To answer these research questions, samples will be collected from patients with&#xD;
      a high clinical suspicion of COVID-19, hospitalized at UZ Gent and 2 participating hospitals&#xD;
      in Ghent (AZ Maria Middelares en AZ Jan Palfijn).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Actual">July 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of cytokines and chemokines associated with COVID-19 severity and outcome.</measure>
    <time_frame>6 months</time_frame>
    <description>Cytokine and chemokine analysis (U-plex Mesoscale Diagnostics) on the plasma and BAL fluid will be correlated to disease severity and outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of cellular subsets that can predict COVID-19 severity and outcome.</measure>
    <time_frame>6 months</time_frame>
    <description>By using high-dimensional flow cytometry on cryopreserved PBMCs, the investigators will assess whether the phenotype and intracellular signaling can predict COVID-19 severity and disease outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS CoV-2 sequencing.</measure>
    <time_frame>6 months</time_frame>
    <description>Whole genome sequencing and viral metagenomics analysis will be performed on selected nasopharyngeal swabs and bronchoalveolar lavage fluid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single-cell RNA sequencing of BAL fluid and matched PBMC samples.</measure>
    <time_frame>6 months</time_frame>
    <description>Single -cell RNA sequencing will be performed on fresh BAL fluid and matched PBMCs by using 10X Genomics technology. The aim of the project is to study the transcriptional activity in different immune cells in the lung in COVID-19 patients with differing disease severity and compare these to non-COVID-19 respiratory infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of plasma hydroxychloroquine and N-desethylhydroxychloroquine (REVIVE).</measure>
    <time_frame>6 months</time_frame>
    <description>In this pilot substudy (REVIVE study), the investigators aim to measure plasma hydroxychloroquine, measuring range 10-2250 ng/mL, and the active metabolite, plasma N-desethylhydroxychloroquine, measuring range 2-2250 ng/m, in patients treated with hydroxychloroquine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of micronutrients Cu, Fe and Zn in plasma samples from COVID-19 + and COVID-19 - patients.</measure>
    <time_frame>12 months</time_frame>
    <description>Total serum or plasma concentrations (mg/L) of Cu, Fe and Zn will be measured using a benchtop TXRF spectrometer (S4 T-STAR, Bruker Nano GmbH, Berlin, Germany) by prof. Gijs Du Laing and the laboratory of Prof. Lutz Schomburg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of micronutrient Se in plasma samples from COVID-19 + and COVID-19 - patients.</measure>
    <time_frame>12 months</time_frame>
    <description>Total serum or plasma concentrations (µg/L) of Se will be measured using a benchtop TXRF spectrometer (S4 T-STAR, Bruker Nano GmbH, Berlin, Germany) by prof. Gijs Du Laing and the laboratory of Prof. Lutz Schomburg.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">109</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>COVID-19 positive</arm_group_label>
    <description>Peripheral blood draw:&#xD;
Day 1 of admission: blood draw.&#xD;
Day 7-10 of hospitalization: blood draw.&#xD;
Follow-up consultation: blood draw (selected patients).&#xD;
Bronchoscopic sampling:&#xD;
Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.&#xD;
Swabs for SARS-CoV-2 PCR:&#xD;
Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative.&#xD;
Day 7-14 of hospitalization: NP swab or clinically available alternative will be executed on day 7 repeated weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 negative</arm_group_label>
    <description>Peripheral blood draw:&#xD;
Day 1 of admission: blood draw.&#xD;
Follow-up consultation: blood draw (selected patients).&#xD;
Bronchoscopic sampling:&#xD;
Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.&#xD;
Swabs for SARS-CoV-2 PCR:&#xD;
o Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.</description>
    <arm_group_label>COVID-19 negative</arm_group_label>
    <arm_group_label>COVID-19 positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoalveolar lavage</intervention_name>
    <description>Only in case of diagnostic or therapeutic indication.</description>
    <arm_group_label>COVID-19 negative</arm_group_label>
    <arm_group_label>COVID-19 positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SARS CoV-2 swabs</intervention_name>
    <description>Nasopharyngeal, oropharyngeal and nasal swabs</description>
    <arm_group_label>COVID-19 negative</arm_group_label>
    <arm_group_label>COVID-19 positive</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (plasma, PBMC), bronchoalveolar lavage fluid, nasopharyngeal swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients hospitalised with symptoms with upper or lower&#xD;
        respiratory symptoms and temperature ≥37.5°C, with high clinical suspicion of COVID-19, who&#xD;
        require hospitalisation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Upper or lower respiratory symptoms and temperature ≥37.5°C, with high clinical&#xD;
             suspicion of COVID-19&#xD;
&#xD;
          -  Requiring hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known pregnancy at the time of screening&#xD;
&#xD;
          -  Inability to give informed consent or absence of legal representative who can give&#xD;
             informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linos Vandekerckhove, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Jan Palfijn</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Ghent</investigator_affiliation>
    <investigator_full_name>Algemene Inwendige Ziekten</investigator_full_name>
    <investigator_title>Prof. Dr. Linos Vandekerckhove</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>6 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

